NCT01652664View on ClinicalTrials.gov

Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Pediatric GlaucomaElevated IOP in Pediatric PatientsOcular Hypertension in Pediatric Patients
Interventions
DRUG

Travoprost 0.004% PQ ophthalmic solution

DRUG

Timolol, 0.5% or 0.25% ophthalmic solution

Patients 2 months to \< 3 years of age received 0.25%

DRUG

Travoprost Vehicle

Inactive ingredients used to maintain masking

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT01652664 - Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients | Biotech Hunter | Biotech Hunter